New-onset diabetic ketoacidosis in a schizophrenic patient with multiple autoimmune disease during treatment with risperidone.
Sato
Yasushi
Y
Yasui-Furukori
Norio
N
Kaneko
Sunao
S
Moriyama
Takako
T
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000453:epidemiology*; D015897:Comorbidity; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008875:Middle Aged; D016884:Polyendocrinopathies, Autoimmune / Q000453:epidemiology; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology
D014150:Antipsychotic Agents; D018967:Risperidone